NCT04754802View on ClinicalTrials.gov

PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge

PHASE3CompletedINTERVENTIONAL
Enrollment

224

Participants

Timeline

Start Date

May 24, 2021

Primary Completion Date

June 22, 2022

Study Completion Date

June 22, 2022

Conditions
Social Anxiety Disorder
Interventions
DRUG

PH94B Nasal Spray

Nasal spray delivered 20 minutes before the public speaking stressor

DRUG

Placebo Nasal Spray

Nasal spray delivered 20 minutes before the public speaking stressor

Trial Locations (21)

10128

VistaGen Clinical Site, New York

18104

VistaGen Clinical Site, Allentown

19063

VistaGen Clinical Site, Media

32256

VistaGen Clinical Site, Jacksonville

32801

VistaGen Clinical Site, Orlando

33614

VistaGen Clinical Site, Tampa

33912

VistaGen Clinical Sites, Fort Myers

60640

VistaGen Clinical Site, Chicago

73106

VistaGen Clinical Site, Oklahoma City

77030

VistaGen Clinical Site, Houston

78229

VistaGen Clinical Site, San Antonio

90024

VistaGen Clinical Site, Los Angeles

91403

VistaGen Clinical Site, Sherman Oaks

92103

VistaGen Clinical Site, San Diego

92503

VistaGen Clinical Site, Riverside

92868

VistaGen Clinical Site, Orange

95124

VistaGen Clinical Site, San Jose

98007

VistaGen Clinical Site, Bellevue

02472

VistaGen Clinical Site, Watertown

08540

VistaGen Clinical Site, Princeton

05091

VistaGen Clinical Site, Woodstock

All Listed Sponsors
lead

VistaGen Therapeutics, Inc.

INDUSTRY